
==== Front
ESMO Open
ESMO Open
ESMO Open
2059-7029
Elsevier

S2059-7029(24)01457-1
10.1016/j.esmoop.2024.103688
103688
Short Communication
Total pain, opioids, and immune checkpoint inhibitors in the survival of patients with cancer
Ripamonti C.I. carla.ripamonti@unibs.it
∗
Chelazzi C.
1 Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
∗ Correspondence to: Prof. Carla Ida Ripamonti, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy carla.ripamonti@unibs.it
30 8 2024
9 2024
30 8 2024
9 9 103688© 2024 The Author(s)
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Experimental and observational studies have shown that opioid analgesics may increase tumor growth, potentially reduce immunotherapy efficacy, and shorten survival. As a result of the lack of clinical data, the current rationale for continuing opioid analgesic treatment is based on animal models, which suggests that physical pain itself may potentially influence cancer growth and exert immunosuppressive effects. Total pain encompasses the various factors that patients may experience during their cancer journey: physical symptoms, social isolation/loneliness, psychological, spiritual/existential, and financial distress. These need to be screened and discussed with patients to help them cope with the treatment and disease. As each issue may affect survival, it is essential to identify them to understand how they might affect the patient’s immune system, influence immunotherapy outcomes, and ultimately, survival. The question arises whether a single factor, such as the combination of opioids and immune checkpoint inhibitors, negatively affects treatment outcomes. While there is a risk of fostering opioid phobia, the complex interplay between total pain, quality of life, and the immune system must be considered. Thus, in studies that appropriately investigate the interactions between opioid analgesics and the immune system, it is essential to consider all the distress factors that patients may experience at each stage of their illness.

Highlights

• Opioids are essential drugs for the treatment of moderate to severe pain in patients with cancer.

• Experimental studies showed that opioids may increase tumor growth, reduce immunotherapy efficacy, and shorten survival.

• Physical pain itself was found to potentially influence cancer growth and exert immunosuppressive effects.

• Psychological distress, loneliness/social isolation, spiritual pain, and financial problems can suppress the immune system.

• Many factors come into play in analyzing the interaction between the immune system and the survival of patients with cancer.

Key words

opioids
total pain
immune checkpoint inhibitors
cancer
survival
==== Body
pmcExperimental and observational studies have suggested that opioids, via the hypothalamic–pituitary–adrenal axis, may increase tumor growth, increase risk of infection, potentially reduce immunotherapy efficacy,1 and shorten survival.1

However, robust clinical evidence about the immune and endocrine effects of opioids on patients with cancer is absent.1, 2, 3, 4

Immune checkpoint inhibitors (ICIs) for primary malignancies are prescribed in both adjuvant and neoadjuvant settings and administered until the late stages of life.5 Given the negative interaction between ICIs, antibiotics, corticosteroids, and paracetamol, prospective studies involving large samples are needed to determine whether the concomitant use of other drugs such as opioids reduces the efficacy of ICIs and shortens survival.4,6

As a result of the lack of clinical data, current evidence1, 2, 3, 4 for continuing opioid analgesic treatment is based on animal models,1 which suggest that physical pain itself may potentially influence cancer growth and exert immunosuppressive effects through the increased release of endogenous opioids. In addition, because the possible negative effects of opioids on survival appear to be dose related, the lowest effective dose of opioids can be recommended,3 and the dosage gradually increased as needed and combined with non-opioid analgesics (adjuvants and nonsteroid anti-inflammatory drugs) and/or nerve blocks to keep the opioid dose low.7

If opioid-related reduced survival were demonstrated in patients treated with immunotherapy, managing their pain would become very difficult at any stage of the disease, and particularly at the end of life, because currently we have no alternatives.

As many patients with cancer experience intense perioperative pain during disease, withholding opioids would be unethical because of exposing these patients to possibly unbearable pain. Moreover, opioids relieve dyspnea and psychological distress, thus improving patients’ quality of life.

The indication1, 2, 3 for gradually increasing opioid dosage, so-called opioid titration, is well-known to pain therapists and palliative care specialists.7 All available options should be considered and used for everyone to minimize the required opioid dose.

Currently, experimental data do not allow us to estimate the effect size of opioids on tumor growth and survival, so there is no reason to suspend their use if they are necessary for pain relief.

Until data are available on the impact of opioids on tumor growth and survival in patients treated with immunotherapy, there is no reason to suspend opioid therapy.

An approach that includes careful listening to the patient, thorough examination, and patient-reported outcomes8 on pain intensity, as well as physical and psychological symptoms, is crucial for assessing the type (neuropathic or somatic), intensity, causes, sites, and triggers of pain.7

However, is it appropriate to focus only on drugs that may interfere with survival, without also considering the impact of psychosocial and spiritual factors on immunity and survival in patients with cancer?

Without incorporating the concept of ‘total pain’ as described by Cecily Saunders,9 physical assessment alone is insufficient. Total pain encompasses various factors that patients may experience during their cancer journey: physical symptoms, social isolation and loneliness, psychological, spiritual/existential, and financial distress. These factors also need to be screened, assessed, and discussed with patients to help them cope with the treatment and the disease. As each problem may impact survival, it is important to identify them to understand how they might affect the patient’s immune system and influence immunotherapy and survival.

‘Total pain’ is a complex syndrome with many dimensions and addressing some components may help alleviate others, including physical pain, thereby potentially reducing opioid requirements.

A clinical examination that does not identify these factors may result in prescribing higher doses of opioid medications without first addressing the total pain. Proper evaluation of total pain might reduce the need for opioids or higher doses.

This is the rationale for asking patients about psychological distress, financial worries related to their illness, spiritual pain, and social isolation. Initial responses should be collected and reviewed for initial screening before proceeding with more detailed investigations using validated instruments as needed.10

Psychological distress

Depression, which can occur at any stage of illness, including among long-term cancer survivors,11 is estimated to affect approximately one in four patients with cancer. These patients are five times more likely to experience depression than the general population.11 Anxiety and depression have been linked to cancer incidence and survival11,12 and can interfere with treatment adherence, as well as weaken the immune system’s resistance to active disease.

The body’s inflammatory response and the tumor microenvironment are linked to psychological distress through the immune system.12 Chronic psychological distress can reduce the efficacy of anti-programmed death-ligand 1 (PD-L1) immunotherapy,12 whereas antidepressants such as imipramine and amitriptyline can exert positive effects on the immune system.12 When used in conjunction with PD-L1 antibodies, these antidepressants can work in synergy to inhibit tumor growth.12 This underscores the importance of screening for psychological symptoms, assessing them with validated tools, and monitoring them closely.

Antidepressants such as amitriptyline and duloxetine, which are central to treating neuropathic pain, can often reduce the need for higher opioid doses when used in combination treatment.7 Effective management of anxiety and depressive disorders in cancer settings is primarily achieved through psychotherapeutic and psychopharmacological approaches, often with the assistance of specialists.11

Financial distress/toxicity

Financial distress can arise at diagnosis, during initial and ongoing treatment, at the end of life, and among survivors.13 It has been linked to clinically relevant outcomes, such as health-related quality of life (HRQoL), symptom burden, treatment compliance, and survival during treatment.13

Stress or worry over medical expenses is reported by 22%-64% of patients with cancer and their caregivers.14 Greater financial distress leads to greater psychological distress, particularly among patients with cancer who are at risk for severe emotional distress, anxiety, and depression.10 This distress can result in delayed diagnoses and reduced adherence to treatment.14,15

Financial toxicity was reported by 26% of 3670 study patients and was strongly correlated with worse global quality of life at baseline. Financial toxicity predicted a greater likelihood of worse HRQoL scores (odds ratio 1.35, 95% confidence interval 1.08-1.70, P = 0.009). During treatment, 22.5% of patients reported financial toxicity, which was significantly associated with an increased risk of death (hazard ratio 1.20, 95% confidence interval 1.05-1.37, P = 0.007).16 Conversely, screening and intervention for financial toxicity in patients with hematologic malignancies have been linked to better quality of life and longer survival.17

Spiritual pain

In their recent systematic review and process-based analysis of quality evidence and expert consensus concerning spirituality in serious illness and health, Balboni et al.18 identified key implications for patient care and health outcomes. Of the 8946 records retrieved, 371 met the inclusion criteria for serious illness, with 76.9% having low-to-moderate risk of bias. The review concluded that spiritual care should be routinely incorporated into the medical care of patients with serious illnesses. Up to 99% of patients report having spiritual needs, and the provision of spiritual care was associated with improved end-of-life outcomes and QoL. In addition, frequent attendance at religious services was associated with a lower risk of mortality, and a dose–response association was observed between attendance and reduced mortality risk,18 as well as the incidence of depression.18

Social isolation and loneliness

Experimental and observational evidence suggests that social isolation and loneliness can exert unique and independent effects on the endocrine and immune systems through the hypothalamic–pituitary–adrenal axis,19, 20, 21 and are associated with an increased risk of early mortality. A cancer diagnosis is a stressful event that heightens distress, and stressors can predict loneliness. Emotional loneliness is a common source of distress and is closely correlated with depression.19

Moreover, loneliness is a distressing experience, especially in the period following initial treatment. Social support can extend the survival of patients with cancer. Possible explanations are that instrumental support improves accessibility to healthcare, while emotional support reduces stress and may enhance immune response. Higher mortality rates among patients with cancer have been linked to a lack of close relatives, friends, or living children.22

During a 29-month follow-up, and after controlling for diverse factors (e.g. age, sex, chronic disease, alcohol and tobacco use, performance status), Penninx et al.23 found that loneliness predicted all-cause mortality and that immunity might be suppressed in lonely individuals. In addition, lonely individuals may experience worse outcomes when they are ill than their nonlonely counterparts.24

Many factors influence the interaction between the immune system and the survival of patients with cancer. The question arises whether a single factor, such as the combination of opioids and ICIs, negatively affects treatment outcomes. While more evidence is needed, we believe the answer is more complex and involves evaluating total pain. Although there is a risk of fostering opioid phobia, which we aim to address, the complex interplay between total pain, quality of life, and the immune system must be considered.

While the total pain experienced by patients with cancer may not be fully alleviated by opioid use alone, patients benefit from being asked simple questions, being listened to by a multidisciplinary care team, and being adequately managed. Can this impact their experience in a way that alters the immune system more than the use of single drugs? We need evidence to confirm that. Thus, in studies that appropriately investigate the interactions between opioid analgesics and the immune system, it is essential to consider all the distress factors that patients with cancer may experience at each stage of their illness.

Funding

None declared.

Disclosure

The authors have declared no conflicts of interest.
==== Refs
References

1 Bradley A. Boland J.W. Effects of opioids on immune and endocrine function in patients with cancer pain Curr Treat Options Oncol 24 2023 867 879 37145383
2 Boland J.W. Effect of opioids on survival in patients with cancer Cancers (Basel) 14 22 2022 5720 36428812
3 Sun M. Chang C.-L. Lu C.-Y. Zhang J. Wu S.-Y. Effect of opioids on cancer survival in patients with chronic pain: a propensity score-matched population-based cohort study Br J Anaesth 128 4 2022 708 717 35144799
4 Cani M. Bironzo P. Garetto F. Buffoni L. Cotogni P. Immune checkpoint inhibitors and opioids in patients with solid tumours: is their association safe? A systematic literature review Healthcare (Basel) 11 1 2022 116 36611575
5 Santini D. Zeppola T. Russano M. PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort J Transl Med 19 1 2021 270 34167578
6 Giusti R. Porzio G. Maltoni M. Association of opioid use with survival in patients with cancer treated with immune checkpoint inhibitors: it is time for evidence-based behaviors Oncologist 2024 oyae081
7 Fallon M. Giusti R. Aielli F. ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines Ann Oncol 29 suppl 4 2018 iv149 iv174
8 Di Maio M. Basch E. Denis F. ESMO Guideline Committee. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guidelines Ann Oncol 33 9 2022 878 892 35462007
9 Clark D. ‘Total pain’, disciplinary power and the body in the work of Cicely Saunders, 1958-1967 Soc Sci Med 49 1990 727 736
10 Ripamonti C.I. Leporati R. De Feo G. Italian version of the Edmonton symptom assessment system (ESAS)-total care (TC): development and psychometric validation in patients undergoing cancer treatment or follow-up Support Care Cancer 30 3 2022 1923 1933 34623487
11 Grassi L. Caruso R. Riba M.B. ESMO Guidelines Committee. Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline ESMO Open 8 2 2023 101155
12 Gui H. Chen X. Li L. Psychological distress influences lung cancer: advances and perspectives on the immune system and immunotherapy Int Immunopharmacol 121 2023 110251
13 Carrera P.M. Curigliano G. Santini D. ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer ESMO Open 9 5 2024 102992
14 Knight T.G. Deal A.M. Dusetzina S.B. Financial toxicity in adults with cancer: adverse outcomes and noncompliance J Oncol Pract 14 2018 JOP1800120
15 Hazell S.Z. Fu W. Hu C. Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life Ann Oncol 31 1 2020 96 102 31912803
16 Perrone F. Jommi C. Di Maio M. The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy Ann Oncol 27 12 2016 2224 2229 27789469
17 Knight T.G. Aguiar M. Robinson M. Financial toxicity intervention improves outcomes in patients with hematologic malignancy JCO Oncol Pract 18 9 2022 e1494 e1504 35709421
18 Balboni T.A. VanderWeel T.J. Doan-Soares S.D. Spirituality in serious illness and health J Am Med Assoc 328 2 2022 184 197
19 Zilioli S. Jiang Y. Endocrine and immunomodulatory effects of social isolation and loneliness across adulthood Psychoneuroendocrinology 128 2021 105194
20 Trachtenberg E. The beneficial effects of social support and prosocial behavior on immunity and health: a psychoneuroimmunology perspective Brain Behav Immun Health 37 2024 100758
21 Scatà C. Carandina A. Della Torre A. Social isolation: a narrative review on the dangerous liaison between the autonomic nervous system and inflammation Life (Basel) 13 6 2023 1229 37374012
22 Wang F. Gao Y. Han Z. A systematic review and meta-analysis of 90 cohort studies of social isolation, loneliness and mortality Nat Hum Behav 7 8 2023 1307 1319 37337095
23 Penninx B.W. van Tilburg T. Kriegsman D.M. Deeg D.J. Boeke A.J. van Eijk J.T. Effects of social support and personal coping resources on mortality in older age: the longitudinal aging study Amsterdam Am J Epidemiol 146 1997 510 519 9290512
24 Baarck J. Kovacic M. The Relationship Between Loneliness and Health: EUR 31155 EN 2022 Publications Office of the European Union Luxembourg
